Atezolizumab Plus Nab-Paclitaxel Approved in Europe for Frontline TNBC

Aug 29, 2019 – The European Commission (EC) has approved the frontline combination of atezolizumab plus nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC), according to Roche (Genentech), the manufacturer of the PD-L1 inhibitor. The approval, which is for patients with a PD-L1 expression level ≥1%, is based on data from the phase III IMpassion130 trial, in which the … (leggi tutto)